中国临床药理学杂志2024，Vol.40Issue(12)：1835-1838,4.DOI:10.13699/j.cnki.1001-6821.2024.12.029
用于前列腺癌患者PSMA PET显像的Piflufolastat F 18
Piflufolastat F 18 for PSMA PET imaging in prostate cancer
石静天 1杨婷 2陈超阳 2魏然 2张玄龄 2胡晓娟 3周颖4
作者信息
- 1. 北京大学第一医院药剂科,北京 100034||北京大学第一医院宁夏妇女儿童医院/宁夏回族自治区妇幼保健院药剂科,宁夏回族自治区银川 750001
- 2. 北京大学第一医院药剂科,北京 100034
- 3. 北京大学第一医院宁夏妇女儿童医院/宁夏回族自治区妇幼保健院药剂科,宁夏回族自治区银川 750001
- 4. 北京大学第一医院药剂科,北京 100034||北京大学第一医院药物临床试验机构,北京 100034
- 折叠
摘要
Abstract
On May 27,2021,the U.S.Food and Drug Administration(FDA)officially approved Lantheus'PYLARIFY®(Piflufolastat F 18,18 F-labeled imaging agent),which can be used for positron emission computed tomography(PET)of prostate-specific membrane antigen(PSMA)-positive lesions in prostate cancer patients to accurately identify prostate cancer with suspected metastasis or recurrence.Piflufolastat F 18 is approved by FDA for two indications.The first is the initial staging for suspected metastatic lesions in men with newly diagnosed prostate cancer.The second is restaging,with the goal of identifying lesions in the setting of biochem ical recurrence.关键词
Piflufolastat F 18/前列腺癌/前列腺特异性膜抗原/正电子发射型计算机断层显像Key words
Piflufolastat F 18/prostate cancer/prostate specific membrane antigen/positron emission computed tomography分类
医药卫生引用本文复制引用
石静天,杨婷,陈超阳,魏然,张玄龄,胡晓娟,周颖..用于前列腺癌患者PSMA PET显像的Piflufolastat F 18[J].中国临床药理学杂志,2024,40(12):1835-1838,4.
